At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
Febuxostat +1 moredrug
Likely dose
Febuxostat 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
In Brief
A Phase 2 clinical trial evaluating Febuxostat and Placebo for Hypertension. Completed, enrolled 121 participants across 45 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with gout).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartFeb 2012
Primary CompletionAug 2014
TodayJul 2026
First PostedDec 21, 2011
Enrollment StartFeb 1, 2012
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.5 years ago
Interventions
Febuxostatdrug
Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
Placebodrug
Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.